Limei Min, Xiaolu Wang, Anni Chen, Yingling Zhou, Yuchen Ge, Juanjuan Dai, Xiaofeng Chang, Wu Sun, Qin Liu, Xia Zhou, Manman Tian, Wentao Kong, Junmeng Zhu, Jie Shen, Baorui Liu, Rutian Li
Background: The authors' preclinical study has confirmed that RO adjuvant (composed of TLR 7 agonists [imiquimod/R837] and OX40 agonists) injected into local lesions induces the regression of both primary tumor and distant metastasis. The authors propose to realize local control and exert abscopal effect through an 'R-ISV-RO' in situ strategy plus anti-PD-1 monoclonal antibody in advanced tumors. Methods: This study is a single-center, exploratory, phase II trial to evaluate the efficacy and safety of R-ISV-RO plus anti-PD-1 monoclonal antibody in advanced tumors...
March 6, 2024: Future Oncology